Abbott settles another part of US Tricor antitrust litigation
11 January 2010
Nancy Faigen
Abbott Laboratories has agreed to pay 23 states and the District of Columbia $22.5 million to settle claims that the company blocked generic drug makers from coming onto the US market with their versions of the branded hypolipaemic Tricor (micronised fenofibrate) through anticompetitive actions involving...
Please Login to read the full article.
11 January 2010
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: After muddled messages, Republicans unite again on Medicare overhaul
- US Capitol Capsule: And they're off: First Supreme Court health reform briefs filed
- US Capitol Capsule: Taking aim at cost reductions, Senate panel chief puts bull's-eye on biopharma
- US Capitol Capsule: Use of mind-altering medicines in children, elderly under fire
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
